NCT06435845View on ClinicalTrials.gov

Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Fetal and Neonatal Alloimmune Thrombocytopenia
Interventions
DRUG

Anti-(integrin beta-3) human monoclonal antibody

human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody

Trial Locations (3)

2333

Leids Universitair Medisch Centrum, Leiden

0450

Oslo University Hospital- Ullevål, Oslo

118 83

Södersjukhuset, Stockholm

Sponsors

Lead Sponsor

Rallybio
All Listed Sponsors
lead

Rallybio

INDUSTRY

NCT06435845 - Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization | Biotech Hunter | Biotech Hunter